Results 131 to 140 of about 61,179 (292)
Drug-drug interactions in repeat prescriptions at village dispensaries (bereg) in Malta [PDF]
, 2013 Inappropriate treatments and drug-drug interactions (DDIs) are known to occur in settings where repeat prescriptions are issued. In view of this, a study was carried out to document any such problematic drug prescribing and propose changes that would
Bugeja, Anton
core
Does the initiation of urate lowering treatment during an acute gout attack prolong the current episode and precipitate recurrent attacks: a systematic literature review [PDF]
, 2016 Objectives: To systematically review the literature on effect of initiating urate lowering treatment (ULT) during an acute attack of gout on duration of index attack and persistence on ULT.
A. Abhishek +12 more
core +2 more sources
European Journal of Haematology, Volume 116, Issue 2, Page 160-168, February 2026.ABSTRACT Acute myeloid leukemia (AML) in elderly patients presents a major therapeutic challenge, as many are deemed unfit for intensive chemotherapy due to age, comorbidities, or frailty. Venetoclax in combination with hypomethylating agents (HMA) has emerged as a standard‐of‐care for this population, yet outcomes remain heterogeneous and predictive ...
Ernesto Vigna +11 more
wiley +1 more source
OP0169 INPATIENT DISCONTINUATION OF ALLOPURINOL – A QUALITATIVE IMPROVEMENT (QI) INITIATIVE [PDF]
, 2022 S. Farshad +4 more
openalex +1 more source
Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study
Arthritis Research & Therapy, 2019 BackgroundFor patients with recurrent flares of gout, tophi, urate crystal arthropathy, and renal stones, urate-lowering therapies (ULTs, including allopurinol and febuxostat) are the first-line treatment.
Amayelle Rey +6 more
semanticscholar +1 more source
European Journal of Haematology, Volume 116, Issue 2, Page 129-141, February 2026.ABSTRACT Relapsed/refractory (R/R) mantle cell lymphoma (MCL) remains a therapeutic challenge, particularly in patients with high‐risk features or prior exposure to Bruton's tyrosine kinase inhibitors (BTKis). The advent of T‐cell–redirecting immunotherapies, including chimeric antigen receptor T‐cell (CAR‐T) therapy and bispecific antibodies (BsAbs ...
Santino Caserta +10 more
wiley +1 more source
Evaluation of a 12-week allopurinol-lowering therapy in combination with the non-steroidal anti-inflammatory drug meloxicam in patients with gout [PDF]
, 2020 Margarita Aleksandrovna Gromova +3 more
openalex +1 more source
Pharmacological Reviews, 2006 The prototypical xanthine oxidase (XO) inhibitor allopurinol, has been the cornerstone of the clinical management of gout and conditions associated with hyperuricemia for several decades.
P. Pacher, A. Nivorozhkin, C. Szabó
semanticscholar +1 more source
Potential role of NADPH-oxidase in early steps of lead-induced oxidative burst in Vicia faba roots [PDF]
, 2008 The mechanism of oxidative burst induced by lead in Vicia faba excised roots was investigated by luminol-dependent chemiluminescence. Results showed that lead triggered a rapid and dose-dependent increase in chemiluminescence production.
Cecchi, Marie +5 more
core +3 more sources